7 active not recruiting, 7 recruiting, 5 completed, 2 not yet recruiting. 12 Phase 2, 4 Phase 1, 2 Phase 4, 1 Early Phase 1.
Follow larotrectinib: new trials by email Literature Review of larotrectinib trials Research Report on larotrectinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy Larotrectinib, Pembrolizumab - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 22 | 2027-03-01 | 2026-09-28 |
| Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study Dabrafenib, Trametinib, Selpercatinib - Thyroid Neoplasms | Phase 4 | Not yet recruiting | Fujian Medical University | 335 | 2025-07-01 | 2025-06-08 |
| Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. Sunvozertinib, Crizotinib, Pralsetinib - Lung Cancer Stage III, Mutation | Phase 2 | Recruiting | Sun Yat-sen University | 120 | 2024-11-01 | 2026-04-21 |
| Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer Alectinib, Cetuximab, Crizotinib - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2022-09-27 | 2023-02-21 |
| A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database Larotrectinib (Vitrakvi, BAY2757556), Standard of Care - Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion, Infantile Fibrosarcoma | Completed | Bayer | 93 | 2022-03-10 | 2024-12-10 | |
| A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice Larotrectinib(Vitrakvi, BAY2757556), Data on other treatments - Solid Tumors Harboring NTRK Fusion | Completed | Bayer | 368 | 2021-12-03 | 2023-11-14 | |
| NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes Larotrectinib (Vitrakvi, BAY2757556) - Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion | Recruiting | Bayer | 100 | 2021-11-05 | 2026-07-07 | |
| Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer Anlotinib, Lenvatinib, Sorafenib - Locally Advanced Thyroid Gland Carcinoma | Phase 2 | Recruiting | West China Hospital | 75 | 2021-06-01 | 2024-12-05 |
| Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors Larotrectinib Sulfate - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 13 | 2021-04-30 | 2026-10-07 |
| A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion Larotrectinib, Larotrectinib surgical - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Early Phase 1 | Recruiting | Nationwide Children's Hospital | 15 | 2021-04-08 | 2026-03-18 |
| Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body larotrectinib(Vitrakvi, BAY2757556) - Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion | Active not recruiting | Bayer | 54 | 2020-04-03 | 2026-10-22 | |
| A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer dabrafenib plus trametinib with or without PD-1 antibody, entrectinib or larotrectinib with or without anti-PD-1 antibdoy, pralsetinib or selpercatinib with or without anti-PD-1 antibdoy - Advanced Thyroid Cancer Patients Who Received Target Therapy | Phase 4 | Recruiting | Fudan University | 800 | 2020-01-01 | 2025-08-14 |
| Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia Larotrectinib Sulfate - Central Nervous System Neoplasm, Infantile Fibrosarcoma | Phase 2 | Active not recruiting | Children's Oncology Group | 33 | 2019-10-25 | 2025-12-02 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 9 | 2017-08-23 | 2026-06-17 |
| Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 16 | 2017-08-21 | 2026-09-01 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
| Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Multiple drug microinjection, CIVO device - Soft Tissue Sarcoma Adult | Phase 1 | Completed | Presage Biosciences | 23 | 2016-12-15 | 2021-09-24 |
| A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children Larotrectinib (Vitrakvi, BAY2757556) - Solid Tumors Harboring NTRK Fusion | Phase 1 / Phase 2 | Active not recruiting | Bayer | 154 | 2015-12-16 | 2025-06-22 |
| A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors BAY2757556 (Larotrectinib, Vitrakvi) - Solid Tumors Harboring NTRK Fusion | Phase 2 | Completed | Bayer | 215 | 2015-09-30 | 2026-07-01 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-22 |
Showing 20 of 22. Sign in to see all of them.
Glioma (4) · Sarcoma (4) · Central Nervous System Neoplasms (3) · Colorectal Neoplasms (3) · Thyroid Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Ependymoma (2) · Hepatoblastoma (2) · Histiocytosis, Langerhans-Cell (2) · Lung Neoplasms (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Medulloblastoma (2) · Melanoma (2)
Bayer (8) · National Cancer Institute (NCI) (4) · M.D. Anderson Cancer Center (2) · Children's Oncology Group (1) · Fudan University (1) · Fujian Medical University (1) · Nationwide Children's Hospital (1) · Oslo University Hospital (1) · Presage Biosciences (1) · Sun Yat-sen University (1) · West China Hospital (1)
United States (14) · China (7) · Canada (6) · Australia (4) · France (4) · Germany (4) · Italy (3) · Japan (3) · Puerto Rico (3) · South Korea (3) · Spain (3) · Sweden (3) · Argentina (2) · Belgium (2) · Czechia (2)
David S Hong (2) · David Hong, MD (1) · Donald W Parsons (1) · Dongmei Ji, M.D (1) · Gary Deutsch, MD (1) · Katherine A Janeway (1) · Keith T Flaherty (1) · Kenneth Gundle, MD (1) · Maryam Fouladi, MD (1) · Qinghai Ji, M.D (1) · Seth Pollack, MD (1) · Si-Yu Wang, MD (1) · Susan Chi, MD (1) · Theodore W Laetsch (1) · Tormod K Guren, MDPhD (1)
PMID 37934000, PMID 29466156, PMID 32105622, PMID 33435412, PMID 33467570, PMID 36606522, PMID 36689698, PMID 37769113, PMID 40267388, PMID 34850167, PMID 35085007, PMID 35536733, PMID 39869835, PMID 40341199, PMID 42614029, PMID 26216294, PMID 26586415, PMID 27974047, PMID 29606586, PMID 30204247, PMID 30624546, PMID 31605106, PMID 31738425, PMID 32223937, PMID 32299817, PMID 32463741, PMID 33048619, PMID 33591402, PMID 34237031, PMID 35133871, PMID 35138919, PMID 35353553, PMID 35672677, PMID 36351402, PMID 37053535, PMID 37133249, PMID 37322121, PMID 38096907, PMID 38591867, PMID 39073712, PMID 39652801, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40304938, PMID 40865033, PMID 41066729, PMID 41166674, PMID 41213248, PMID 42686334
U10CA180886 (3), U10CA180820 (2), 2015 (1), 2016 (1), U24CA196172 (1)